Latest Torcetrapib Stories

Connie K. Ho for RedOrbit.com High-density lipoprotein, otherwise known as HDL, was thought to be “good” cholesterol. However, a new study, based on databases of genetic information, disproves the HDL theory and states that rising HDL may not have any change to heart disease risk. As such, people who have inherited genes that have a high amount of HDL do not have any less of a chance of having heart disease than those who have inherited genes that have lower levels of HDL. According...

Researchers at Cleveland Clinic reported today that administration of a new drug– evacetrapib – can dramatically increase HDL (good) cholesterol, while significantly lowering LDL (bad) cholesterol). At the highest tested dosage, the levels of HDL more than doubled. The study was presented today by lead investigator Stephen Nicholls MD PhD, Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5), at the American Heart Association's Scientific...

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease. The study is being released early online to coincide with its presentation at the American...

US regulators will be considering a plan from pharmaceutical giant Pfizer to introduce an over-the-counter version of its top-selling heart drug Lipitor. Selling the popular anti-cholesterol drug without a prescription could help Pfizer's bottom line as the company faces a "patent cliff" that threatens to erode profits during the next few years, according to the Wall Street Journal.Lipitor will soon lose patent protection and face competition from cheaper generic versions of its popular...

(Ivanhoe Newswire) -- A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to this study.The drug, Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of high-density lipoproteins (HDLs, or "good" cholesterol).The study found that 6,661 people with type 2 diabetes "“ also known as...

A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American Heart Association.Researchers made the finding while analyzing data from a clinical trial on the drug torcetrapib that was halted five years ago. Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of...

HOERSHOLM, Denmark and SAN DIEGO, May 4, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced SPC5001 into Phase 1 clinical trials for the treatment of high cholesterol. SPC5001 is a mRNA-targeted drug that inhibits the exciting new target, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), a protein involved in removing low density...

HDL cholesterol can transform from good to bad actor in heart disease process We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of...

WALTHAM, Mass., Jan. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of dyslipidemia, the rapid uptake of Roche/Japan Tobacco's first-in-class dalcetrapib and Merck's anacetrapib will drive $3.2 billion in sales of the cholesteryl ester transfer protein (CETP) inhibitors drug class in 2018 in the world's major pharmaceutical markets. Anacetrapib and dalcetrapib appear to be...

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests. Scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University  and Boston University School of Medicine found an association between low plasma cholesterol ester transfer protein (CETP) activity and increased risk of heart disease in the Framingham...